Mexico's Cofepris has approved a new therapeutic use for a Bayer drug, allowing personalized, chemotherapy-free treatment options for metastatic hormone-sensitive prostate cancer. This is a significant development in Mexico, where prostate cancer is the leading cause of cancer death among men, with approximately 30,000 new cases diagnosed annually. The approval aims to improve patient quality of life and extend survival.